Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills
Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900
Fax: + 91 40 4900 2999
Email: mail@drreddys.com
Web: www.drreddys.com

November 28, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform that the Company received an order dated November 24, 2026, issued by the Director (FAC) & Licensing Authority, Drugs Control Administration, Vijayawada, from the Office of the Director General of Drugs and Copyrights, Andhra Pradesh, on November 27, 2026. The details required under Regulation 30 read with Schedule III, Part A, Para A (20) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are set out below:

Name of the authority	Director (FAC) & Licensing Authority, Drugs Control Administration, Vijayawada
Nature and details of the action(s) taken, initiated or order(s) passed	Suspension of the manufacturing license of the Company's CTO-SEZ Process Unit-01 manufacturing facility located at Devunipalavalasa Village, Ranastalam Mandal, Srikakulam District, Andhra Pradesh, India, for a period of two (2) days.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	November 27, 2026.
Details of the violation(s)/ contravention(s) committed or alleged to be committed	During an inspection conducted in June 2026 for the said unit, certain observations were made by the authorities. While the Company submitted responses and clarifications to the observations, the authority was not satisfied with the same and has issued the present order.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	Based on the Company's assessment, the said action is not expected to have any material impact on its financial position, operations or other activities. The Company is evaluating appropriate regulatory and corrective measures in this regard, including filing an appeal seeking review of the order.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Dr. Reddy's Laboratories Limited**

Kumar Randhir Singh
Digitally signed by Kumar Randhir Singh
Date: 2026.11.28 16:39:55 +05'30'

K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR